{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:26:24Z","timestamp":1759692384852},"publisher-location":"Berlin, Heidelberg","reference-count":88,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783642137167"},{"type":"electronic","value":"9783642137174"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010]]},"DOI":"10.1007\/7854_2010_45","type":"book-chapter","created":{"date-parts":[[2010,4,20]],"date-time":"2010-04-20T10:07:17Z","timestamp":1271758037000},"page":"23-42","source":"Crossref","is-referenced-by-count":31,"title":["Antipsychotics and Metabolics in the Post-CATIE Era"],"prefix":"10.1007","author":[{"given":"Jonathan M.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,21]]},"reference":[{"key":"45_CR1_45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/schbul\/15.1.81","volume":"15","author":"P Allebeck","year":"1989","unstructured":"Allebeck P (1989) Schizophrenia: a life-shortening disease. Schizophr Bull 15:81\u201389","journal-title":"Schizophr Bull"},{"key":"45_CR2_45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4088\/JCP.v65n0219","volume":"65","author":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity","year":"2004","unstructured":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65:267\u2013272","journal-title":"J Clin Psychiatry"},{"key":"45_CR3_45","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.crd.0000380842.14048.7e","volume":"13","author":"SM Grundy","year":"2005","unstructured":"American Heart Association, National Heart, Lung, and Blood Institute, Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 13:322\u2013327","journal-title":"Cardiol Rev"},{"key":"45_CR4_45","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.4088\/JCP.v65n1007","volume":"65","author":"B Arranz","year":"2004","unstructured":"Arranz B, Rosel P, Ramirez N, Duenas R, Fernandez P, Sanchez JM, Navarro MA, San L (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65:1335\u20131342","journal-title":"J Clin Psychiatry"},{"key":"45_CR5_45","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.298.3.309","volume":"298","author":"S Bansal","year":"2007","unstructured":"Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298:309\u2013316","journal-title":"JAMA"},{"key":"45_CR6_45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2005.09.023","volume":"187","author":"SM Boekholdt","year":"2006","unstructured":"Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, Peters RJG, Jukema JW, Day NE, Kastelein JJP, Khaw K-T (2006) C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993\u20132003. Atherosclerosis 187:415\u2013422","journal-title":"Atherosclerosis"},{"key":"45_CR7_45","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1192\/bjp.171.6.502","volume":"171","author":"S Brown","year":"1997","unstructured":"Brown S (1997) Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 171:502\u2013508","journal-title":"Br J Psychiatry"},{"key":"45_CR8_45","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1017\/S0033291798008186","volume":"29","author":"S Brown","year":"1999","unstructured":"Brown S, Birtwistle J, Roe L, Thompson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychol Med 29:697\u2013701","journal-title":"Psychol Med"},{"key":"45_CR9_45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1192\/bjp.184.47.s67","volume":"184","author":"C Bushe","year":"2004","unstructured":"Bushe C, Holt R (2004) Prevalence of diabetes and glucose intolerance in patients with schizophrenia. Br J Psychiatry 184:67\u201371","journal-title":"Br J Psychiatry"},{"key":"45_CR10_45","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/00006842-196711000-00008","volume":"29","author":"ML Clark","year":"1967","unstructured":"Clark ML, Ray TS, Paredes A, Ragland RE, Costiloe JP, Smith CW, Wolf S (1967) Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol\u2013behavior relationships. Psychosom Med 29:634\u2013642","journal-title":"Psychosom Med"},{"key":"45_CR11_45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/070674370404901106","volume":"49","author":"T Cohn","year":"2004","unstructured":"Cohn T, Prud\u2019homme D, Streiner D, Kameh H, Remington G (2004) Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 49:753\u2013760","journal-title":"Can J Psychiatry"},{"key":"45_CR12_45","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/070674370605100608","volume":"51","author":"TA Cohn","year":"2006","unstructured":"Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TMS (2006) Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 51:382\u2013386","journal-title":"Can J Psychiatry"},{"key":"45_CR13_45","first-page":"1","volume":"3","author":"CW Colton","year":"2006","unstructured":"Colton CW, Manderscheid RW (2006) Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 3:1\u201314","journal-title":"Prev Chronic Dis"},{"key":"45_CR14_45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-145-1-200607040-00128","volume":"145","author":"NR Cook","year":"2006","unstructured":"Cook NR, Buring JE, Ridker PM (2006) The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 145:21\u201329","journal-title":"Ann Intern Med"},{"key":"45_CR15_45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.schres.2008.07.006","volume":"105","author":"GL Daumit","year":"2008","unstructured":"Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck RA, Davis SM, Hsiao JK, Stroup TS, Lieberman JA (2008) Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 105:175\u2013187","journal-title":"Schizophr Res"},{"key":"45_CR16_45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.schres.2005.12.855","volume":"83","author":"MA Hert De","year":"2006","unstructured":"De Hert MA, van Winkel R, van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 83:87\u201393","journal-title":"Schizophr Res"},{"key":"45_CR17_45","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1001\/jama.285.16.2109","volume":"285","author":"F Vegt de","year":"2001","unstructured":"de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ (2001) Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study. JAMA 285:2109\u20132113","journal-title":"JAMA"},{"key":"45_CR18_45","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.schres.2007.03.022","volume":"93","author":"F Dickerson","year":"2007","unstructured":"Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R (2007) C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 93:261\u2013265","journal-title":"Schizophr Res"},{"key":"45_CR19_45","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1001\/jama.283.4.506","volume":"283","author":"BG Druss","year":"2000","unstructured":"Druss BG, Bradford DW, Rosenheck RA, Radford MJ, Krumholz HM (2000) Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA 283:506\u2013511","journal-title":"JAMA"},{"key":"45_CR20_45","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/archinte.163.9.1077","volume":"163","author":"LE Eberly","year":"2003","unstructured":"Eberly LE, Stamler J, Neaton JD, Multiple Risk Factor Intervention Trial Research Group (2003) Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 163:1077\u20131083","journal-title":"Arch Intern Med"},{"key":"45_CR21_45","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/00005053-196606000-00007","volume":"142","author":"HY Efron","year":"1966","unstructured":"Efron HY, Balter AM (1966) Relationship of phenothiazine intake and psychiatric diagnosis to glucose level and tolerance. J Nerv Ment Dis 142:555\u2013561","journal-title":"J Nerv Ment Dis"},{"key":"45_CR22_45","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1161\/01.CIR.36.4.609","volume":"36","author":"FH Epstein","year":"1967","unstructured":"Epstein FH (1967) Hyperglycemia: a risk factor in coronary heart disease. Circulation 36:609\u2013619","journal-title":"Circulation"},{"key":"45_CR23_45","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","unstructured":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486\u20132497","journal-title":"JAMA"},{"key":"45_CR24_45","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.atherosclerosis.2003.12.022","volume":"173","author":"ES Ford","year":"2004","unstructured":"Ford ES (2004) The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173:309\u2013314","journal-title":"Atherosclerosis"},{"key":"45_CR25_45","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.2337\/diacare.27.10.2444","volume":"27","author":"ES Ford","year":"2004","unstructured":"Ford ES, Giles WH, Mokdad AH (2004) Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 27:2444\u20132449","journal-title":"Diabetes Care"},{"key":"45_CR26_45","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/aje\/kwi229","volume":"162","author":"CJ Girman","year":"2005","unstructured":"Girman CJ, Dekker JM, Rhodes T, Nijpels G, Stehouwer CDA, Bouter LM, Heine RJ (2005) An exploratory analysis of criteria for the metabolic syndrome and its prediction of long-term cardiovascular outcomes: the Hoorn study. Am J Epidemiol 162:438\u2013447","journal-title":"Am J Epidemiol"},{"key":"45_CR27_45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.schres.2005.08.010","volume":"80","author":"DC Goff","year":"2005","unstructured":"Goff DC, Sullivan L, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D\u2019Agnostino RB, Stroup TS, Davis S, Lieberman JA (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE Study and matched controls. Schizophr Res 80:45\u201353","journal-title":"Schizophr Res"},{"key":"45_CR28_45","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","volume":"109","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Brewer B, Cleeman JI, Smith SC, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition. Circulation 109:433\u2013438","journal-title":"Circulation"},{"key":"45_CR29_45","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jocn.2005.08.010","volume":"13","author":"J Gunstad","year":"2006","unstructured":"Gunstad J, Bausserman L, Paul RH, Tate DF, Hoth K, Poppas A, Jefferson AL, Cohen RA (2006) C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease. J Clin Neurosci 13:540\u2013546","journal-title":"J Clin Neurosci"},{"key":"45_CR30_45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/01.yic.0000188215.84784.17","volume":"21","author":"S Hagg","year":"2006","unstructured":"Hagg S, Lindblom Y, Mjorndal T, Adolfsson R (2006) High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 21:93\u201398","journal-title":"Int Clin Psychopharmacol"},{"key":"45_CR31_45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group (2002) MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7\u201322","journal-title":"Lancet"},{"key":"45_CR32_45","doi-asserted-by":"publisher","first-page":"575","DOI":"10.4088\/JCP.v64n0513","volume":"64","author":"T Heiskanen","year":"2003","unstructured":"Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J (2003) Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 64:575\u2013579","journal-title":"J Clin Psychiatry"},{"key":"45_CR33_45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/sj.npp.1301209","volume":"32","author":"KL Houseknecht","year":"2007","unstructured":"Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H (2007) Acute effects of atypical antipsychotics on whole body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32:289\u2013297","journal-title":"Neuropsychopharmacology"},{"key":"45_CR34_45","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1161\/01.CIR.97.11.1029","volume":"97","author":"J Jeppesen","year":"1998","unstructured":"Jeppesen J, Hein HO, Suadicani P, Gyntelberg F (1998) Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 97:1029\u20131036","journal-title":"Circulation"},{"key":"45_CR35_45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/10401230209147399","volume":"14","author":"H Jin","year":"2002","unstructured":"Jin H, Meyer JM, Jeste DV (2002) Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 14:59\u201364","journal-title":"Ann Clin Psychiatry"},{"key":"45_CR36_45","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","volume":"63","author":"PB Jones","year":"2006","unstructured":"Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63:1079\u20131087","journal-title":"Arch Gen Psychiatry"},{"key":"45_CR37_45","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.2337\/diacare.28.9.2289","volume":"28","author":"R Kahn","year":"2005","unstructured":"Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal. Diabetes Care 28:2289\u20132304","journal-title":"Diabetes Care"},{"key":"45_CR38_45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/01.CIR.59.1.8","volume":"59","author":"WB Kannel","year":"1979","unstructured":"Kannel WB, McGee DL (1979) Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59:8\u201313","journal-title":"Circulation"},{"key":"45_CR39_45","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1592\/phco.22.11.841.33629","volume":"22","author":"EA Koller","year":"2002","unstructured":"Koller EA, Doraiswamy PM (2002) Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841\u2013852","journal-title":"Pharmacotherapy"},{"key":"45_CR40_45","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S0002-9343(01)01000-2","volume":"111","author":"E Koller","year":"2001","unstructured":"Koller E, Schneider B, Bennett K, Dubitsky G (2001) Clozapine-associated diabetes. Am J Med 111:716\u2013723","journal-title":"Am J Med"},{"key":"45_CR41_45","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223","journal-title":"N Engl J Med"},{"key":"45_CR42_45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2337\/dc06-1414","volume":"30","author":"C Lorenzo","year":"2007","unstructured":"Lorenzo C, Williams K, Hunt KJ, Haffner SM (2007) The National Cholesterol Education Program \u2013 Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30:8\u201313","journal-title":"Diabetes Care"},{"key":"45_CR43_45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1192\/bjp.bp.106.031716","volume":"191","author":"P Mackin","year":"2007","unstructured":"Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier IN (2007) Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 191:23\u201329","journal-title":"Br J Psychiatry"},{"key":"45_CR44_45","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","volume":"161","author":"SR Marder","year":"2004","unstructured":"Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161:1334\u20131349","journal-title":"Am J Psychiatry"},{"key":"45_CR45_45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","volume":"80","author":"JP McEvoy","year":"2005","unstructured":"McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial and comparison with national estimates from NHANES III. Schizophr Res 80:19\u201332","journal-title":"Schizophr Res"},{"key":"45_CR46_45","doi-asserted-by":"crossref","first-page":"802","DOI":"10.7326\/0003-4819-139-10-200311180-00007","volume":"139","author":"T McLaughlin","year":"2003","unstructured":"McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G (2003) Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139:802\u2013809","journal-title":"Ann Intern Med"},{"key":"45_CR47_45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/00005053-195808000-00009","volume":"127","author":"RB Mefferd","year":"1958","unstructured":"Mefferd RB, Labrosse EH, Gawienowski AM, Williams RJ (1958) Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. J Nerv Ment Dis 127:167\u2013179","journal-title":"J Nerv Ment Dis"},{"issue":"Suppl 27","key":"45_CR48_45","first-page":"27","volume":"62","author":"JM Meyer","year":"2001","unstructured":"Meyer JM (2001a) Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 62(Suppl 27):27\u201334, discussion 40\u201341","journal-title":"J Clin Psychiatry"},{"key":"45_CR49_45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00004714-200108000-00003","volume":"21","author":"JM Meyer","year":"2001","unstructured":"Meyer JM (2001b) Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 21:369\u2013374","journal-title":"J Clin Psychopharmacol"},{"key":"45_CR50_45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2004.01.014","volume":"70","author":"JM Meyer","year":"2004","unstructured":"Meyer JM, Koro CE (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1\u201317","journal-title":"Schizophr Res"},{"key":"45_CR51_45","volume-title":"Medical illness and schizophrenia","author":"JM Meyer","year":"2009","unstructured":"Meyer JM, Nasrallah HA (2009) Medical illness and schizophrenia, 2nd edn. American Psychiatric Press, Washington, DC","edition":"2"},{"key":"45_CR52_45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/00131746-200601000-00002","volume":"12","author":"J Meyer","year":"2006","unstructured":"Meyer J, Loh C, Leckband SG, Boyd JA, Wirshing WC, Pierre JM, Wirshing D (2006) Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 12:5\u201310","journal-title":"J Psychiatr Pract"},{"key":"45_CR53_45","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.schres.2008.04.023","volume":"103","author":"JM Meyer","year":"2008","unstructured":"Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA (2008a) Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 103:104\u2013109","journal-title":"Schizophr Res"},{"key":"45_CR54_45","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","volume":"101","author":"JM Meyer","year":"2008","unstructured":"Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA (2008b) Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 101:273\u2013286","journal-title":"Schizophr Res"},{"key":"45_CR55_45","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.biopsych.2009.06.005","volume":"66","author":"JM Meyer","year":"2009","unstructured":"Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao J, Swartz MS, Stroup TS, Lieberman JA (2009a) Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the CATIE effective study. Biol Psychiatry 66:1013\u20131022","journal-title":"Biol Psychiatry"},{"key":"45_CR56_45","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4088\/JCP.08m04267","volume":"70","author":"JM Meyer","year":"2009","unstructured":"Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R (2009b) The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. J Clin Psychiatry 70:318\u2013325","journal-title":"J Clin Psychiatry"},{"key":"45_CR57_45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.schres.2006.06.026","volume":"86","author":"HA Nasrallah","year":"2006","unstructured":"Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA (2006) Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE Schizophrenia Trial sample at baseline. Schizophr Res 86:15\u201322","journal-title":"Schizophr Res"},{"issue":"Suppl 1","key":"45_CR58_45","first-page":"1","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl 1):1\u201393","journal-title":"CNS Drugs"},{"key":"45_CR59_45","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1001\/jama.298.15.1794","volume":"298","author":"JW Newcomer","year":"2007","unstructured":"Newcomer JW, Hennekens CH (2007) Severe mental illness and risk of cardiovascular disease. JAMA 298:1794\u20131796","journal-title":"JAMA"},{"key":"45_CR60_45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jama.298.3.299","volume":"298","author":"BG Nordestgaard","year":"2007","unstructured":"Nordestgaard BG, Benn M, Schnohr P, Tybj\u00e6rg-Hansen A (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299\u2013308","journal-title":"JAMA"},{"key":"45_CR61_45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0920-9964(99)00191-7","volume":"45","author":"U Osby","year":"2000","unstructured":"Osby U, Correia N, Brandt L, Ekbom A, Sparen P (2000a) Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45:21\u201328","journal-title":"Schizophr Res"},{"key":"45_CR62_45","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/bmj.321.7259.483","volume":"321","author":"U Osby","year":"2000","unstructured":"Osby U, Correia N, Brandt L, Ekbom A, Sparen P (2000b) Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 321:483\u2013484","journal-title":"BMJ"},{"key":"45_CR63_45","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2337\/diabetes.37.12.1595","volume":"37","author":"GM Reaven","year":"1988","unstructured":"Reaven GM (1988) Banting lecture 1988: role of insulin resistance in human disease. Diabetes 37:1595\u20131607","journal-title":"Diabetes"},{"key":"45_CR64_45","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa021993","volume":"347","author":"PM Ridker","year":"2002","unstructured":"Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557\u20131565","journal-title":"N Engl J Med"},{"key":"45_CR65_45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E (2005) Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20\u201328","journal-title":"N Engl J Med"},{"key":"45_CR66_45","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFayden JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, Group JTS (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195\u20132207","journal-title":"N Engl J Med"},{"key":"45_CR67_45","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1176\/appi.ajp.160.2.284","volume":"160","author":"MCM Ryan","year":"2003","unstructured":"Ryan MCM, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284\u2013289","journal-title":"Am J Psychiatry"},{"key":"45_CR68_45","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.lfs.2003.08.044","volume":"74","author":"MCM Ryan","year":"2004","unstructured":"Ryan MCM, Flanagan S, Kinsella U, Keeling F, Thakore JH (2004) The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 74:1999\u20132008","journal-title":"Life Sci"},{"key":"45_CR69_45","doi-asserted-by":"publisher","first-page":"559","DOI":"10.4088\/JCP.v66n0503","volume":"66","author":"KM Saari","year":"2005","unstructured":"Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin M-R, Lauren LH, Savolainen MJ, Koponen HJ (2005) A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 66:559\u2013563","journal-title":"J Clin Psychiatry"},{"key":"45_CR70_45","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","volume":"64","author":"S Saha","year":"2007","unstructured":"Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64:1123\u20131131","journal-title":"Arch Gen Psychiatry"},{"key":"45_CR71_45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1176\/ajp.125.2.253","volume":"125","author":"L Schwarz","year":"1968","unstructured":"Schwarz L, Munoz R (1968) Blood sugar levels in patients treated with chlorpromazine. Am J Psychiatry 125:253\u2013255","journal-title":"Am J Psychiatry"},{"key":"45_CR72_45","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","volume":"165","author":"L Sikich","year":"2008","unstructured":"Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA (2008) Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420\u20131431","journal-title":"Am J Psychiatry"},{"key":"45_CR73_45","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.mcna.2007.06.008","volume":"91","author":"DA Smith","year":"2007","unstructured":"Smith DA (2007) Treatment of the dyslipidemia of insulin resistance. Med Clin North Am 91:1185\u20131210","journal-title":"Med Clin North Am"},{"key":"45_CR74_45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1464-5491.2007.02092.x","volume":"24","author":"LM Spelman","year":"2007","unstructured":"Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH (2007) Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 24:481\u2013485","journal-title":"Diabet Med"},{"key":"45_CR75_45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-244X-7-14","volume":"7","author":"M Srisurapanont","year":"2007","unstructured":"Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N (2007) Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 7:14","journal-title":"BMC Psychiatry"},{"key":"45_CR76_45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/appi.ajp.163.4.611","volume":"163","author":"TS Stroup","year":"2006","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (2006) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611\u2013622","journal-title":"Am J Psychiatry"},{"key":"45_CR77_45","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.4088\/JCP.v68n0711","volume":"68","author":"JM Suvisaari","year":"2007","unstructured":"Suvisaari JM, Saarni SI, Perala J, Suvisaari JVJ, Harkanen T, Lonnqvist J, Reunanen A (2007) Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 68:1045\u20131055","journal-title":"J Clin Psychiatry"},{"key":"45_CR78_45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/sj.ijo.0801840","volume":"26","author":"JH Thakore","year":"2002","unstructured":"Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R (2002) Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 26:137\u2013141","journal-title":"Int J Obes Relat Metab Disord"},{"key":"45_CR79_45","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1080\/00048670701392841","volume":"41","author":"S Tirupati","year":"2007","unstructured":"Tirupati S, Chua L-E (2007) Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust NZ J Psychiatry 41:606\u2013610","journal-title":"Aust NZ J Psychiatry"},{"key":"45_CR80_45","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1210\/jc.2007-1167","volume":"93","author":"LJ Nimwegen van","year":"2008","unstructured":"van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Venema HW, de Haan L, Becker H, van Amelsvoort T, Ackermans MT, Fliers E, Serlie MJ, Sauerwein HP (2008) Hepatic insulin resistance in antipsychotic naive patients with schizophrenia, a detailed study of glucose metabolism with stable isotopes. J Clin Endocrinol Metab 93:572\u2013577","journal-title":"J Clin Endocrinol Metab"},{"key":"45_CR81_45","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1176\/appi.ajp.2007.07020233","volume":"164","author":"G Venkatasubramanian","year":"2007","unstructured":"Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN, Thirthall J, Gangadhar BN, Shetty KT (2007) Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 164:1557\u20131560","journal-title":"Am J Psychiatry"},{"key":"45_CR82_45","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1001\/archinte.165.22.2644","volume":"165","author":"SG Wannamethee","year":"2005","unstructured":"Wannamethee SG, Shaper AG, Lennon L, Morris RW (2005) Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 165:2644\u20132650","journal-title":"Arch Intern Med"},{"key":"45_CR83_45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.jcp.0000095347.32154.08","volume":"23","author":"PJ Weiden","year":"2003","unstructured":"Weiden PJ, Daniel DG, Simpson GM, Romano SJ (2003) Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 23:1\u20136","journal-title":"J Clin Psychopharmacol"},{"key":"45_CR84_45","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/sj.npp.1301482","volume":"33","author":"PJ Weiden","year":"2008","unstructured":"Weiden PJ, Newcomer JW, Loebel A, Yang R, Lebovitz H (2008) Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 33:985\u2013994","journal-title":"Neuropsychopharmacology"},{"key":"45_CR85_45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/01.ede.0000198183.60572.c9","volume":"17","author":"J Weuve","year":"2006","unstructured":"Weuve J, Ridker PM, Cook NR, Buring JE, Grodstein F (2006) High-sensitivity C-reactive protein and cognitive function in older women. Epidemiology 17:183\u2013189","journal-title":"Epidemiology"},{"key":"45_CR86_45","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1001\/jama.298.22.2654","volume":"298","author":"C Willi","year":"2007","unstructured":"Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J (2007) Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 298:2654\u20132664","journal-title":"JAMA"},{"key":"45_CR87_45","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","volume":"97","author":"PW Wilson","year":"1998","unstructured":"Wilson PW, D\u2019Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837\u20131847","journal-title":"Circulation"},{"key":"45_CR88_45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1192\/bjp.184.1.58","volume":"184","author":"Z-J Zhang","year":"2004","unstructured":"Zhang Z-J, Yao Z-J, Liu W, Fang Q, Reynolds GP (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184:58\u201362","journal-title":"Br J Psychiatry"}],"container-title":["Current Topics in Behavioral Neurosciences","Behavioral Neurobiology of Schizophrenia and Its Treatment"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2010_45","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T09:49:42Z","timestamp":1635241782000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/7854_2010_45"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"ISBN":["9783642137167","9783642137174"],"references-count":88,"URL":"https:\/\/doi.org\/10.1007\/7854_2010_45","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"type":"print","value":"1866-3370"},{"type":"electronic","value":"1866-3389"}],"subject":[],"published":{"date-parts":[[2010]]}}}